Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk

Purpose: The study compared the incidence of cancer between patients with diabetes with and without sodiumglucose cotransporter-2 (SGLT2) inhibitors use. Methods: This study identified a non-SGLT2 inhibitor cohort of 325,989 patients and a SGLT2 inhibitor cohort of 325,990 patients. The primary interest of this study was the occurrence of cancer. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models. Results: Patients receiving SGLT2 inhibitors (adjusted HR = 0.79, 95 % CI = 0.76-0.83) had a significantly lower risk of developing cancer than patients without receiving SGLT2 inhibitors. Conclusion: The results demonstrated that patients with diabetes receiving SGLT2 inhibitors had a significantly lower risk of cancer.